+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors



Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors



Antimicrobial Agents and ChemoTherapy 40(10): 2300-2305



Some Candida albicans isolates from AIDS patients with oropharyngeal candidiasis are becoming resistant to the azole antifungal agent fluconazole after prolonged treatment with this compound. Most of the C. albicans isolates resistant to fluconazole fail to accumulate this antifungal agent, and this has been considered a cause of resistance. This phenomenon was shown to be linked to an increase in the amounts of mRNA of a C. albicans ABC (ATP-binding cassette) transporter gene called CDR1 and of a gene conferring benomyl resistance (BEN-r), the product of which belongs to the class of major facilitator multidrug efflux transporters (D. Sanglard, K. Kuchler, F. Ischer, J. L. Pagani, M. Monod, and J. Bille, Antimicrob. Agents Chemother. 39:2378-2386, 1995). To analyze the roles of these multidrug transporters in the efflux of azole antifungal agents, we constructed C. albicans mutants with single and double deletion mutations of the corresponding genes. The mutants were tested for their susceptibilities to these antifungal agents. Our results indicated that the DELTA-cdr1 C. albicans mutant was hypersusceptible to the azole derivatives fluconazole, itraconazole, and ketoconazole, thus showing that the ABC transporter Cdr1 can use these compounds as substrates. The DELTA-cdr1 mutant was also hypersusceptible to other antifungal agents (terbinafine and amorolfine) and to different metabolic inhibitors (cycloheximide, brefeldin A, and fluphenazine). The same mutant was slightly more susceptible than the wild type to nocodazole, cerulenin, and crystal violet but not to amphotericin B, nikkomycin Z, flucytosine, or pradimicin. In contrast, the DELTA-ben mutant was rendered more susceptible only to the mutagen 4-nitroquinoline-N-oxide. However, this mutation increased the susceptibilities of the cells to cycloheximide and cerulenin when the mutation was constructed in a DELTA-cdr1 background. The assay used in the present study could be implemented with new antifungal agents and is a powerful tool for assigning these substances as putative substrates of multidrug transporters.

(PDF emailed within 0-6 h: $19.90)

Accession: 002973219

Download citation: RISBibTeXText

PMID: 8891134

DOI: 10.1128/aac.40.10.2300


Related references

Susceptibility of Candida albicans multidrug transporters mutants to different antifungal agents. Abstracts of the General Meeting of the American Society for Microbiology 96(0): 151, 1996

Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology Reading 143(2): 405-416, 1997

Comparisons of the susceptibilities of planktonic and adherent Candida albicans to antifungal agents: a modified XTT tetrazolium assay using synchronised C. albicans cells. Journal of Medical and Veterinary Mycology 34(2): 149-152, 1996

In Vitro Susceptibilities of Candida albicans Isolates to Antifungal Agents in Tokat, Turkey. Jundishapur Journal of Microbiology 8(9): E28057, 2015

Substitution of threonine-1351 in the multidrug transporter Cdr1p of Candida albicans results in hypersusceptibility to antifungal agents and threonine-1351 is essential for synergic effects of calcineurin inhibitor FK520. Journal of Antimicrobial ChemoTherapy 54(1): 38-45, 2004

Substrates and modulators of the multidrug transporter Cdr1p of Candida albicans in antifungal extracts of medicinal plants. Mycoses 53(4): 305-310, 2010

Characteristics and resistance properties associated with biofilm formation by Candida albicans multidrug transporter mutants. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 362, 2001

Candida albicans mutants in the ergosterol biosynthetic pathway and their resistance to several antifungal agents. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 363, 2000

Susceptibilities of Candida albicans mouth isolates to antifungal agents, essentials oils and mouth rinses. Mycopathologia 174(1): 69-76, 2012

Comparison of in vitro antifungal susceptibilities of candida albicans and candida tropicalis adhered to urinary catheter. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 31: 232, 1991

Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrobial Agents and ChemoTherapy 39(11): 2378-2386, 1995

Inhibitors of the glyoxylate cycle enzyme ICL1 in Candida albicans for potential use as antifungal agents. Plos One 9(4): E95951, 2015

In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012. Mycoses 58(4): 209-214, 2015

Inhibitory Effect of Antifungal Agents on Germ Tube Formation in Candida albicans. Hemmeffekt antifungaler Wirkstoffe auf die Keimschlauchbildung von Candida albicans. Mycoses 30(6): 281-287, 1987

Deletion of transmembrane domain 12 of CDR1, a multidrug transporter from Candida albicans, leads to altered drug specificity: expression of a yeast multidrug transporter in baculovirus expression system. Yeast 14(6): 535-550, 1998